The traditional Chinese medicine sector soared! Many stocks such as Jinling Pharmaceutical and Teyi Pharmaceutical closed with a high limit

【Pharmaceutical Network Pharmaceutical Stock Market】On November 14, the traditional Chinese medicine sector rose
sharply again.
According to data from the Oriental Fortune Network Market Information Center, as of the close of the 14th, many stocks such as Jinling Pharmaceutical, Teyi Pharmaceutical, Zhongsheng Pharmaceutical, and Sunflower Pharmaceutical closed with a price limit, Yiling Pharmaceutical, Tailong Pharmaceutical, Huluwa, etc
.
rose by more than 7%, and Guizhou Bailing, Huasen Pharmaceutical, etc.
followed suit.
The analysis believes that the reasons for Jinling Pharmaceutical's limit increase include several aspects: the company's main business is drug production, sales and medical pension services
.
In terms of drug production, the company's main products are Choronin injection (mainly used for thromboangiitis obliterans, arteriosclerotic occlusion, cerebral thrombosis and sequelae, multiple Takayasu arteritis, acute arterial embolism of the extremities, diabetic gangrene, venous thrombosis and thrombophlebitis, etc.
), ferrous succinate tablets (Sulifei, mainly used for the prevention and treatment of iron deficiency anemia), lentinan injection (mainly used for adjuvant treatment of malignant tumors), etc.
, of which the company "Choronin injection" The process method is listed in the "Catalogue of State Secret Technology Projects" (Chinese proprietary medicine), and the secret level is secret
.
The company has the relevant invention patent of "Meiluoning injection"; In terms of medical service business, it is mainly provided by Suqian Hospital, Yizheng Hospital and Anqing Hospital under the company; The elderly care rehabilitation business is provided by Huzhou Development (including rehabilitation specialized hospitals)
under the company.
The reasons for the price limit of Teyi Pharmaceutical include: the company focuses on characteristic Chinese medicines, has a characteristic Chinese patent medicine type of cough suppressant tablets for cold cough, and has successively acquired Hainan Haili and Guangdong Guoyitang Drugs (approved assets), and added many varieties
such as skin disease blood poison pills and hypoglycemic pills.
Huaxin Securities once said in a research report that after the market of its cough tablets is fully expanded, the sales space is expected to exceed 500 million yuan
in the next 5 years.
The company's sales focus on the core varieties of proprietary Chinese medicine, focusing on cultivating skin disease blood poison pills, hypoglycemic pills, maple stomach health tablets, cold spirit granules and other products, promoting the emergence of large varieties and enhancing the brand value
of "special one".
In addition, the company also acquired 25% of the shares of Teyimei with cash, officially entering the medical beauty service sector
.
The reasons for the price limit of Zhongsheng Pharmaceutical include: the company is an enterprise that focuses on innovative drugs, Chinese proprietary medicines, and chemical generic drugs, and the existing product pipeline covers ophthalmology, cardiovascular and cerebrovascular, respiratory, digestive, gynecological and other major disease fields, with a complete product layout and reasonable echelon, in line with national industrial policies and drug policies, and can meet the needs
of the whole terminal market 。 The innovative drug pipeline covers respiratory, tumor and metabolic diseases and other therapeutic fields, and through industry-university-research cooperation and the company's technology transformation, it has formed a short, medium and long-term product R&D portfolio of innovative drugs, improved new drugs, generic drugs, generic drug consistency evaluation, and post-marketing re-evaluation of proprietary Chinese medicines, which continues to inject impetus
into the company's development.
Sunflower Pharmaceutical is a large-scale brand pharmaceutical group enterprise that integrates drug R&D, manufacturing and marketing with the production of proprietary Chinese medicines as the main and "chemical drugs, biological drugs" and "health products" as the two wings
.
The company's variety reserve is more than 1,000.

Focusing on the "Little Sunflower" children's drug cluster, the gynecological drugs and the old and chronic disease cluster in the "Sunflower" adult medicine, the company continues to improve the diagnosis and treatment promotion plan, do real category marketing, and strengthen OTC marketing
.
The agency pointed out that at present, the traditional Chinese medicine sector is obviously favorable on the supply and demand side, and the fundamentals of traditional Chinese medicine companies have reported relatively good performance in the third quarter of this year, and it is expected that many segments are expected to usher in rapid development, and can focus on the consumer areas with low gross profit and high sales, as well as areas with brand premiums and brand barriers
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.